Show simple item record

dc.creatorKotsiou O.S., Gourgoulianis K.I., Zarogiannis S.G.en
dc.date.accessioned2023-01-31T08:44:48Z
dc.date.available2023-01-31T08:44:48Z
dc.date.issued2018
dc.identifier10.3389/fimmu.2018.02432
dc.identifier.issn16643224
dc.identifier.urihttp://hdl.handle.net/11615/75215
dc.description.abstractInterleukin 33 (IL-33) is highly expressed in barrier sites, acting via the suppression of tumorigenicity 2 receptor (ST2). IL-33/ST2 axis has long been known to play a pivotal role in immunity and cell homeostasis by promoting wound healing and tissue repair. However, it is also involved in the loss of balance between extensive inflammation and tissue regeneration lead to remodeling, the hallmark of fibrosis. The aim of the current review is to critically evaluate the available evidence regarding the role of the IL-33/ST2 axis in organ fibrosis. The role of the axis in tissue remodeling is better understood considering its crucial role reported in organ development and regeneration. Generally, the IL-33/ST2 signaling pathway has mainly anti-inflammatory/anti-proliferative effects; however, chronic tissue injury is responsible for pro-fibrogenetic responses. Regarding pulmonary fibrosis mature IL-33 enhances pro-fibrogenic type 2 cytokine production in an ST2- and macrophage-dependent manner, while full-length IL-33 is also implicated in the pulmonary fibrotic process in an ST2-independent, Th2-independent fashion. In liver fibrosis, evidence indicate that when acute and massive liver damage occurs, the release of IL-33 might act as an activator of tissue-protective mechanisms, while in cases of chronic injury IL-33 plays the role of a hepatic fibrotic factor. IL-33 signaling has also been involved in the pathogenesis of acute and chronic pancreatitis. Moreover, IL-33 could be used as an early marker for ulcer-associated activated fibroblasts and myofibroblast transdifferentiation; thus one cannot rule out its potential role in inflammatory bowel disease-associated fibrosis. Similarly, the upregulation of the IL-33/ST2 axismay contribute to tubular cell injury and fibrosis via epithelial to mesenchymal transition (EMT) of various cell types in the kidneys. Of note, IL-33 exerts a cardioprotective role via ST2 signaling, while soluble ST2 has been demonstrated as a marker of myocardial fibrosis. Finally, IL-33 is a crucial cytokine in skin pathology responsible for abnormal fibroblast proliferation, leukocyte infiltration and morphologic differentiation of human endothelial cells. Overall, emerging data support a novel contribution of the IL-33/ST2 pathway in tissue fibrosis and highlight the significant role of the Th2 pattern of immune response in the pathophysiology of organ fibrosis. © 2018 Kotsiou, Gourgoulianis and Zarogiannis.en
dc.language.isoenen
dc.sourceFrontiers in Immunologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85055857338&doi=10.3389%2ffimmu.2018.02432&partnerID=40&md5=531568f8de1a42e2765dd60d1b0c483d
dc.subjectbiological markeren
dc.subjectgalectin 3en
dc.subjectinterleukin 1 receptoren
dc.subjectinterleukin 33en
dc.subjectprotein kinase B betaen
dc.subjectstress activated protein kinase 1en
dc.subjectsuppression of tumorigenicity 2 receptoren
dc.subjecttransforming growth factor betaen
dc.subjectunclassified drugen
dc.subjectautacoiden
dc.subjectbiological markeren
dc.subjectcytokineen
dc.subjectinterleukin 1 receptor like 1 proteinen
dc.subjectinterleukin 33en
dc.subjectacute kidney failureen
dc.subjectangiogenesisen
dc.subjectapoptosisen
dc.subjectcell damageen
dc.subjectcell differentiationen
dc.subjectcell proliferationen
dc.subjectdisease exacerbationen
dc.subjectepithelial mesenchymal transitionen
dc.subjectfibroblasten
dc.subjectfibrogenesisen
dc.subjectfibrosisen
dc.subjectgene expressionen
dc.subjectheart muscle fibrosisen
dc.subjectheart protectionen
dc.subjecthomeostasisen
dc.subjectimmune responseen
dc.subjectimmunityen
dc.subjectinflammationen
dc.subjectinflammatory bowel diseaseen
dc.subjectintestinal fibrosisen
dc.subjectkidney fibrosisen
dc.subjectliver cirrhosisen
dc.subjectlung fibrosisen
dc.subjectMAPK signalingen
dc.subjectmultiple sclerosisen
dc.subjectnonhumanen
dc.subjectoxidative stressen
dc.subjectpancreatitisen
dc.subjectReviewen
dc.subjectsignal transductionen
dc.subjectskin fibrosisen
dc.subjectsystemic lupus erythematosusen
dc.subjecttissue repairen
dc.subjectupregulationen
dc.subjectwound healingen
dc.subjectanimalen
dc.subjectantibody specificityen
dc.subjectfibrosisen
dc.subjectgeneticsen
dc.subjecthumanen
dc.subjectimmunologyen
dc.subjectmetabolismen
dc.subjectpathologyen
dc.subjectsignal transductionen
dc.subjectTh2 cellen
dc.subjectAnimalsen
dc.subjectBiomarkersen
dc.subjectCytokinesen
dc.subjectFibrosisen
dc.subjectHumansen
dc.subjectInflammation Mediatorsen
dc.subjectInterleukin-1 Receptor-Like 1 Proteinen
dc.subjectInterleukin-33en
dc.subjectOrgan Specificityen
dc.subjectSignal Transductionen
dc.subjectTh2 Cellsen
dc.subjectFrontiers Media S.A.en
dc.titleIL-33/ST2 axis in organ fibrosisen
dc.typeotheren


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record